STAT+: AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion
AbbVie said it will buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major depression, a sign that pharma is warming up more to the burgeoning field.